Targeting escape mutations
in hematological cancers
with first and best in class medicines
A small molecule oncology drug discovery company that is committed to defeating cancer.
At Eilean Therapeutics we are developing pan-variant therapies for hematologic malignancies that target the major drivers of cancer resistance, helping to overcome the limitations of current oncology therapeutics.
Our Recent Publications
EiIean Therapeutics Presents Novel Wild-Type Sparing, Reversible Pan-EGFR Inhibitor at AACR-NCI-EORTC International Conference
Eilean Therapeutics Advances ZE74-0282, a Highly Selective Inhibitor of Mutated JAK2 V617F, into First-in-Human Clinical Development
